<SEC-DOCUMENT>0001193125-19-047774.txt : 20190222
<SEC-HEADER>0001193125-19-047774.hdr.sgml : 20190222
<ACCEPTANCE-DATETIME>20190222084032
ACCESSION NUMBER:		0001193125-19-047774
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190222
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190222
DATE AS OF CHANGE:		20190222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		19624038

	BUSINESS ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8582514400

	MAIL ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d711590d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): February&nbsp;22, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Heron Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-33221</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">94-2875566</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>4242 Campus Point Court, Suite 200, San Diego, CA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>92121</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code (858)
<FONT STYLE="white-space:nowrap">251-4400</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Results of Operations and Financial Condition. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, Heron Therapeutics, Inc. (&#147;Company&#148;) issued a press release announcing its financial results for the three and twelve
months ended December&nbsp;31, 2018 (&#147;Earnings Press Release&#148;). A copy of the Earnings Press Release is furnished as Exhibit 99.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Item
2.02 and the Earnings Press Release attached hereto as Exhibit 99.1, insofar as they disclose information regarding the Company&#146;s results of operations or financial condition for the three and twelve months ended December&nbsp;31, 2018, are
being furnished to the Securities and Exchange Commission. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;No.&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d711590dex991.htm">Earnings Press Release, dated February&nbsp;22, 2019 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Heron Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;22, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert E. Hoffman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert E. Hoffman</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer&nbsp;&amp; Senior Vice President, Finance</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d711590dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g711590heron.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Heron Therapeutics Announces Financial Results for the Three and Twelve </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Months Ended December&nbsp;31, 2018 and Recent Corporate Progress </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN DIEGO, Calif.&#151;(BUSINESS WIRE)&#151;February&nbsp;22, 2019&#151; Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company
focused on improving the lives of patients by developing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatments to address some of the most important unmet patient needs, today reported financial
results for the three and twelve months ended December&nbsp;31, 2018 and highlighted recent corporate progress. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Corporate Progress </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pain Management Franchise </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Acceptance of <FONT STYLE="white-space:nowrap">HTX-011</FONT> NDA for Postoperative Pain Management with
Priority Review Designation; PDUFA Date of April</B><B></B><B>&nbsp;30, 2019: </B>The U.S. Food and Drug Administration (FDA) recently accepted the new drug application (NDA) for Heron&#146;s investigational agent,
<FONT STYLE="white-space:nowrap">HTX-011,</FONT> and has granted it a Priority Review designation. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of April&nbsp;30, 2019 and indicated that it is not currently planning an advisory
committee meeting to discuss this application. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>90% of Patients Treated with <FONT STYLE="white-space:nowrap">HTX-011</FONT> Opioid-Free 72 Hours Post-Surgery
in New Multi-center Clinical Study:</B> In this study, 63 patients undergoing hernia repair surgery received <FONT STYLE="white-space:nowrap">HTX-011</FONT> together with a regimen of generic, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter,</FONT></FONT> oral analgesics (acetaminophen and ibuprofen). Ninety percent (90%) of patients were opioid-free 72 hours post-surgery, and 81% were still opioid-free 28 days post-surgery.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Formal Development Initiated on <FONT STYLE="white-space:nowrap">HTX-034,</FONT> Our Next-Generation Product
Candidate for Postoperative Pain Management:</B> Based on the positive results of preclinical studies in which <FONT STYLE="white-space:nowrap">HTX-034</FONT> demonstrated significant pain reduction for 7 days, Heron has initiated formal development
of this next-generation postoperative pain management product candidate. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CINV Franchise </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>2018 Net Sales:</B> Fourth-quarter 2018 net sales for the chemotherapy-induced nausea and vomiting (CINV)
franchise were $28.8&nbsp;million, up 187% year-over-year and up 46% from the third quarter of 2018. This included net sales of $23.4&nbsp;million for CINVANTI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (aprepitant) injectable
emulsion and $5.4&nbsp;million for SUSTOL<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (granisetron) extended-release injection. Full-year 2018 net sales for the CINV franchise were $77.5&nbsp;million, up 152% year-over-year. This
included net sales of $56.2&nbsp;million for CINVANTI and $21.3&nbsp;million for SUSTOL. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>2019 Net Sales Guidance: </B>Heron expects 2019 net sales for the CINV franchise of $115&nbsp;million to
$120&nbsp;million. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g711590heron.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;2018 was a year of significant growth for our
CINV franchise, and we look forward to continued strong performance this year,&#148;&nbsp;said Barry Quart, Pharm.D., President and Chief Executive Officer of Heron.&nbsp;&#147;In pain management, Heron remains committed to making a significant
impact on the opioid epidemic through the development and commercialization of innovative <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain management products.&nbsp;With a PDUFA goal date of April&nbsp;30, 2019, we look forward to launching <FONT
STYLE="white-space:nowrap">HTX-011</FONT> in the U.S. later this year, if approved.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net product sales for the three and twelve months ended December&nbsp;31, 2018 were $28.8&nbsp;million and $77.5&nbsp;million, respectively, compared to
$10.1&nbsp;million and $30.8&nbsp;million for the same periods in 2017, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron&#146;s net loss for the three and twelve months ended
December&nbsp;31, 2018 was $49.6&nbsp;million and $178.8&nbsp;million, or $0.63 per share and $2.44 per share, respectively, compared to $62.5&nbsp;million and $197.5&nbsp;million, or $1.09 per share and $3.65 per share, for the same periods in
2017, respectively. Net loss for the three and twelve months ended December&nbsp;31, 2018 included <FONT STYLE="white-space:nowrap">non-cash,</FONT> stock-based compensation expense of $9.8&nbsp;million and $33.4&nbsp;million, respectively, compared
to $6.9&nbsp;million and $30.5&nbsp;million, for the same periods in 2017, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, Heron had cash, cash equivalents
and short-term investments of $332.4&nbsp;million, compared to $172.4&nbsp;million as of December&nbsp;31, 2017. Net cash used for operating activities for the three and twelve months ended December&nbsp;31, 2018 was $33.5&nbsp;million and
$191.8&nbsp;million, respectively, compared to $47.1&nbsp;million and $170.3&nbsp;million for the same periods in 2017, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT
STYLE="white-space:nowrap">HTX-011</FONT> for Postoperative Pain </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HTX-011,</FONT> which utilizes Heron&#146;s
proprietary Biochronomer<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> drug delivery technology, is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the
anti-inflammatory meloxicam for postoperative pain management. By delivering sustained levels of both a potent anesthetic and a local anti-inflammatory agent directly to the site of tissue injury, <FONT STYLE="white-space:nowrap">HTX-011</FONT> was
designed to deliver superior pain relief while reducing the need for systemically administered pain medications such as opioids, which carry the risk of harmful side effects, abuse and addiction. <FONT STYLE="white-space:nowrap">HTX-011</FONT> has
been shown to reduce pain significantly better than placebo or bupivacaine solution in five diverse surgical models: hernia repair, abdominoplasty, bunionectomy, total knee arthroplasty and breast augmentation.
<FONT STYLE="white-space:nowrap">HTX-011</FONT> was granted Fast Track designation from the&nbsp;FDA in the fourth quarter of 2017 and Breakthrough Therapy designation in the second quarter of 2018. Heron submitted an NDA to the&nbsp;FDA&nbsp;for <FONT
STYLE="white-space:nowrap">HTX-011</FONT> in October of 2018 and received Priority Review designation in December of 2018. The FDA set a PDUFA goal date of April&nbsp;30, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g711590heron.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CINVANTI (aprepitant) injectable emulsion
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated
with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). CINVANTI is an
intravenous formulation of aprepitant, a substance <FONT STYLE="white-space:nowrap">P/neurokinin-1</FONT> (NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>) receptor antagonist. CINVANTI is the first intravenous (IV)&nbsp;formulation to
directly deliver aprepitant, the active ingredient in EMEND<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK<SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor antagonist to significantly reduce nausea and vomiting in both the acute phase (0 &#150; 24 hours after chemotherapy) and the delayed phase (24 &#150; 120 hours after chemotherapy).
CINVANTI is the only IV formulation of an NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor antagonist indicated for the prevention of acute and delayed nausea and vomiting associated with HEC and nausea and vomiting associated
with MEC that is free of polysorbate 80 or any other synthetic surfactant. Pharmaceutical formulations containing polysorbate 80 have been linked to hypersensitivity reactions, including anaphylaxis and irritation of blood vessels resulting in
infusion-site pain. <FONT STYLE="white-space:nowrap">FDA-approved</FONT> dosing administration included in the United States prescribing information for CINVANTI is a <FONT STYLE="white-space:nowrap">30-minute</FONT> infusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full prescribing information at <U>www.CINVANTI.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About SUSTOL (granisetron) extended-release injection </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and
repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable <FONT STYLE="white-space:nowrap">5-HT</FONT><SUB
STYLE="font-size:85%; vertical-align:bottom">3</SUB> receptor antagonist that utilizes Heron&#146;s Biochronomer<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> drug delivery technology to maintain therapeutic levels of granisetron for <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 days. The SUSTOL global Phase 3 development program was comprised of two, large, guideline-based clinical studies that evaluated SUSTOL&#146;s efficacy and safety in more than 2,000 patients with cancer.
SUSTOL&#146;s efficacy in preventing nausea and vomiting was evaluated in both the acute phase (0 &#150; 24 hours after chemotherapy) and delayed phase (24 &#150; 120 hours after chemotherapy). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full prescribing information at <U>www.SUSTOL.com</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g711590heron.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Heron Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved
pharmacological agents for patients suffering from pain or cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit <U>www.herontx.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains
&#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management&#146;s expectations and assumptions as of the date of this news
release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, those associated with: the full-year 2019 net sales guidance for the CINV franchise; whether the FDA
approves the <FONT STYLE="white-space:nowrap">HTX-011</FONT> NDA as submitted; the timing of the FDA&#146;s review process for <FONT STYLE="white-space:nowrap">HTX-011;</FONT> whether the FDA will require an advisory committee meeting for <FONT
STYLE="white-space:nowrap">HTX-011</FONT> in the future; the anticipated commercial launch of <FONT STYLE="white-space:nowrap">HTX-011;</FONT> the timing and results of the studies in the <FONT STYLE="white-space:nowrap">HTX-034</FONT> development
program; and other risks and uncertainties identified in the Company&#146;s filings with the U.S. Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update
or revise these statements except as may be required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g711590heron.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Condensed Consolidated Statements of Operations </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Twelve Months Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 28,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 10,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 77,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 30,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183,937</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(194,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(62,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(178,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(197,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g711590heron.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Condensed Consolidated Balance Sheet Data </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">332,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">172,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Promissory note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations and Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Szekeres Senior VP, General Counsel, Business Development&nbsp;and Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">dszekeres@herontx.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">858-251-4447</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g711590heron.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g711590heron.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MVDI02C[Z/G<SSK+,@JPHSI^SQ.-?-"$82A&L[VDU54'2=2.C<92C)II]5?\
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MGE^%2YI*.SEM=H^N_P#A;OPH_P"BG?#S_P +3PW_ /+*OC_[(S;_ *%>+_\
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56@UR\JE+>^GME?2GMA0 4 % '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
